Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

What’s Going to Be Hot at ACC 2025?

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

Vaping Linked to Higher Risk of HFpEF, NIH Data Show

News Conference News ACC 2024

Vaping Linked to Higher Risk of HFpEF, NIH Data Show

April 12, 2024

A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyopathy

Presentation ACC 2024

A Selective Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiomyopathy

Presenter: James L. Januzzi Jr

April 08, 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

April 06, 2024

Main Results From The Step-hfpef Dm Trial

Presentation ACC 2024

Main Results From The Step-hfpef Dm Trial

Presenter: Mikhail Kosiborod

April 06, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

News Conference News ACC 2023

How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA

March 09, 2023

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

News Conference News ACC 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

May 16, 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

May 15, 2021

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

News Conference News ACC 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

March 19, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.